• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIVASTIGMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • RIVASTIGMINE chembl:CHEMBL636 Approved

    Alternate Names:

    KERSTIPON
    VOLEZE
    ALZEST
    PROMETAX
    ERASTIG
    SDZ-212-713
    SDZ-ENA-713
    NIMVASTID
    ELUDEN
    ENA-713
    ENA-713D
    SOMNITON
    RIVASTIGMINE
    ONO-2540
    EXELON
    SDZ-212713
    EXELON®
    (S)-3-(1-(DIMETHYLAMINO)ETHYL)PHENYL ETHYLMETHYLCARBAMATE
    M-((S)-1-(DIMETHYLAMINO)ETHYL)PHENYL ETHYLMETHYLCARBAMATE
    ENA 713 FREE BASE
    ENA713
    pubchem.compound:77991
    rxcui:183379
    chembl:CHEMBL636
    chemidplus:123441-03-2
    drugbank:00989

    Drug Info:

    Drug Categories phenylcarbamates
    Drug Categories neuroprotective agents
    Drug Categories bradycardia-causing agents
    Drug Categories anti-dementia drugs
    Year of Approval 2000
    Drug Class nootropic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of Alzheimer's disease
    Drug Categories compounds used in a research, industrial, or household setting
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories parasympathomemetic (cholinergic) agents
    (4 More Sources)

    Publications:

    Gottwald et al., 1999, Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status., Expert Opin Investig Drugs
    Naik et al., 2009, Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice., J Pharm Pharm Sci
    Scacchi R et al., 2009, Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine., Am J Med Genet B Neuropsychiatr Genet
    Lalli et al., 2008, Rivastigmine in Parkinson's disease dementia., Expert Rev Neurother
    Greig et al., 2002, Butyrylcholinesterase: an important new target in Alzheimer's disease therapy., Int Psychogeriatr
    Birks et al., 2009, Rivastigmine for Alzheimer's disease., Cochrane Database Syst Rev
    Grossberg et al., 2000, Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications., Int J Geriatr Psychiatry
    Goldblum et al., 2000, Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits., J Ocul Pharmacol Ther
    Stahl, 2000, The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different., J Clin Psychiatry
    Onor et al., 2007, Rivastigmine in the treatment of Alzheimer's disease: an update., Clin Interv Aging
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kennedy et al., 1999, Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans., J Clin Psychopharmacol
    Farlow, 2003, Update on rivastigmine., Neurologist
    Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease., Cochrane Database Syst Rev
    Han HJ et al., 2015, Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease., Eur Neurol
    Bassil et al., 2009, Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease., CNS Drugs
    Smith, 2009, Treatment of Alzheimer's disease in the long-term-care setting., Am J Health Syst Pharm
    Blesa R et al., 2006, Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease., Pharmacogenet Genomics
    O'Brien KK et al., 2003, Regulation of attention and response to therapy in dementia by butyrylcholinesterase., Pharmacogenetics
    Yoon H et al., 2015, Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease., Pharmacopsychiatry
    Braga IL et al., 2015, Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease., Am J Alzheimers Dis Other Demen
  • RIVASTIGMINE   BCHE

    Interaction Score: 8.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    16437532 11139819 19470293 18780301 18671661 25376930 12636181 19370562 11078030 19374459 18044073 11752352 19420308 17047484 12668920 14587496


    Sources:
    TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • RIVASTIGMINE   ACHE

    Interaction Score: 4.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cholinesterases; ACHE & BCHE inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    PMIDs:
    11139819 19470293 18780301 18671661 12636181 19370562 10713582 10673128 11078030 18044073 11752352 10587286 14587496


    Sources:
    TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • RIVASTIGMINE   CHAT

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25730470


    Sources:
    PharmGKB

  • RIVASTIGMINE   CHRNA7

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24951635


    Sources:
    PharmGKB

  • DrugBank: DB00989

    • Version: 5.1.7

    Alternate Names:
    RIVASTIGMINE DrugBank Drug Name
    123441-03-2 CAS Number
    Act Rivastigmine Patch 10 Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Birks, 2006, Cholinesterase inhibitors for Alzheimer's disease., Cochrane Database Syst Rev
    Gottwald et al., 1999, Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status., Expert Opin Investig Drugs
    Naik et al., 2009, Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice., J Pharm Pharm Sci

  • TEND: RIVASTIGMINE

    • Version: 01-August-2011

    Alternate Names:
    RIVASTIGMINE Primary Drug Name

    Drug Info:
    Drug Class nootropic agents
    Year of Approval 2000

    Publications:

  • TdgClinicalTrial: RIVASTIGMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of Alzheimer's disease
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: rivastigmine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Scacchi R et al., 2009, Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine., Am J Med Genet B Neuropsychiatr Genet
    Braga IL et al., 2015, Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease., Am J Alzheimers Dis Other Demen
    Yoon H et al., 2015, Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease., Pharmacopsychiatry

  • GuideToPharmacology: 178103215

    • Version: 29-September-2020

    Alternate Names:
    RIVASTIGMINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Rivastigmine

    • Version: 2020.06.01

    Alternate Names:
    D0WY5Q TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL636

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL636

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2021-04-13